A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancers

Clinical Colorectal Cancer

Volumn 13, Issue 2, 2014, Pages 81-86

  Denlinger, Crystal S ^a   Meropol, Neal J ^b   Li, Tianyu ^a   Lewis, Nancy L ^c   Engstrom, Paul F ^a   Weiner, Louis M ^d   Cheng, Jonathan D ^a   Alpaugh, R Katherine ^a   Cooper, Harry ^a   Wright, John J ^e   Cohen, Steven J ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^d GEORGETOWN UNIVERSITY   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Biliary tract cancers; Bortezomib; Cholangiocarcinoma; Proteosome inhibition

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; BORTEZOMIB; CREATININE; BORONIC ACID DERIVATIVE; PROTEASOME INHIBITOR; PYRAZINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BILE DUCT CARCINOMA; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; CHOLECYSTECTOMY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; DEHYDRATION; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EARLY TERMINATION OF CLINICAL TRIAL; EDEMA; FATIGUE; FEMALE; GALLBLADDER CARCINOMA; GASTROINTESTINAL OBSTRUCTION; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; KIDNEY FAILURE; LEUKOPENIA; LIVER RESECTION; MALE; MENINGITIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RASH; SENSORY NEUROPATHY; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; ULCER; VOMITING; ADENOCARCINOMA; BILE DUCT NEOPLASMS; CHOLANGIOCARCINOMA; CLINICAL TRIAL; DISEASE COURSE; FOLLOW UP; GALLBLADDER NEOPLASMS; INTRAHEPATIC BILE DUCT; MIDDLE AGED; PATHOLOGY; TIME; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; BORONIC ACIDS; CHOLANGIOCARCINOMA; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GALLBLADDER NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PROTEASOME INHIBITORS; PYRAZINES; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84900492900     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2013.12.005     Document Type: Article

References (50)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 2012 10 29
2. P.C. de Groen, G.J. Gores, and N.F. LaRusso et al. Biliary tract cancers N Engl J Med 341 1999 1368 1378
3. D.E. Henson, J. Albores-Saavedra, and D. Code Carcinoma of the gallbladder. Histologic types, stage of disease, grade, and survival rates Cancer 70 1992 1493 1497
4. D.E. Henson, J. Albores-Saavedra, and D. Corle Carcinoma of the extrahepatic bile ducts. Histologic types, stage of disease, grade, and survival rates Cancer 70 1992 1498 1501
5. G. Falkson, J.M. Macintyre, and C.G. Moertel Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer Cancer 54 1984 965 969
6. M. Ducreux, P. Rougier, and A. Fandi et al. Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin Ann Oncol 9 1998 653 656
7. Y. Patt, D. Jones, and A. Hoque et al. Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer J Clin Oncol 14 1996 2311 2315
8. T. Okusaka, H. Ishii, and A. Funakoshi et al. Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer Cancer Chemother Pharmacol 57 2006 647 653
9. J.O. Gallardo, B. Rubio, and M. Fodor et al. A phase II study of gemcitabine in gallbladder carcinoma Ann Oncol 12 2001 1403 1406
10. P. Papakostas, C. Kouroussis, and N. Androulakis et al. First-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract. A multicentre phase II study Eur J Cancer 37 2001 1833 1838
11. P.M. Sanz-Altamira, E. O'Reilly, and K.E. Stuart et al. A phase II trial of irinotecan (CPT-11) for unresectable biliary tree carcinoma Ann Oncol 12 2001 501 504
12. J. Adams Development of the proteasome inhibitor PS-341 Oncologist 7 2002 9 16
13. S.V. Rajkumar, P.G. Richardson, and T. Hideshima et al. Proteasome inhibition as a novel therapeutic target in human cancer J Clin Oncol 23 2005 630 639
14. A.-M. Hui, X. Li, and Y.-Z. Shi et al. p27Kip1 expression in normal epithelia, precancerous lesions, and carcinomas of the gallbladder: Association with cancer progression and prognosis Hepatology 31 2000 1068 1072
15. M. Fiorentino, A. Altimari, and A. D'Errico et al. Low p27 expression is an independent predictor of survival for patients with either hilar or peripheral intrahepatic cholangiocarcinoma Clin Cancer Res 7 2001 3994 3999
16. K.-I. Taguchi, S.-I. Aishima, and Y. Asayama et al. The role of p27kip1 protein expression on the biological behavior of intrahepatic cholangiocarcinoma Hepatology 33 2001 1118 1123
17. A.-M. Hui, X. Cui, and M. Makuuchi et al. Decreased p27kip1 expression and cyclin D1 overexpression, alone or in combination, influence recurrence and survival of patients with resectable extrahepatic bile duct carcinoma Hepatology 30 1999 1167 1173
18. D.M. Harnois, F.G. Que, and A. Celli et al. Bcl-2 is overexpressed and alters the threshold for apoptosis in a cholangiocarcinoma cell line Hepatology 26 1997 884 890
19. A. Tannapfel, L. Weinans, and F. Geibler et al. Mutations of p53 tumor suppressor gene, apoptosis, and proliferation in intrahepatic cholangiocellular carcinoma of the liver Dig Dis Sci 45 2000 317 324
20. L. Xoapfang, Z. Shengquan, and Q. Fazu Expression of nuclear factor kappa B in hepatitis C virus core gene transfected cholangiocarcinoma cells Chin Med J 115 2002 998 1001
21. Ustundag, S.F. Bronk, and G.J. Gores Proteasome inhibition induces endoplasmic reticulum dysfunction and cell death of human cholangiocarcinoma cells World J Gastroenterol 13 2007 851 857
22. V. Baradari, M. Hopfner, and A. Huether et al. Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells World J Gastroenterol 13 2007 4458 4466
23. K. Vaeteewoottacharn, R. Kariya, and K. Matsuda et al. Perturbation of proteasome function by bortezomib leading to ER stress-induced apoptotic cell death in cholangiocarcinoma J Cancer Res Clin Oncol 139 2013 1551 1562
24. B.A. Teicher, G. Ara, and R. Herbst et al. The proteasome inhibitor PS-341 in cancer therapy Clin Cancer Res 5 1999 2638 2645
25. Millennium Pharmaceuticals. Velcade Package Insert. 2011; http://www.velcade.com/. Accessed May 25, 2011.
26. C. Aghajanian, S. Soignet, and D.S. Dizon et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies Clin Cancer Res 8 2002 2505 2511
27. S.R. Alberts, H. Al-Khatib, and M.R. Mahoney et al. Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma Cancer 103 2005 111 118
28. T. André, C. Tournigand, and O. Rosmorduc et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study Ann Oncol 15 2004 1339 1343
29. J.Y. Cho, Y.H. Paik, and Y.S. Chang et al. Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma Cancer 104 2005 2753 2758
30. J.J. Knox, D. Hedley, and A. Oza et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial J Clin Oncol 23 2005 2332 2338
31. F. Verderame, A. Russo, and R. Di Leo et al. Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers Ann Oncol 17 2006 vii68 vii72
32. U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events version 3.0. 2006. Available at: http://ctep.cancer.gov/ protocoldevelopment/electronic-applications/docs/ctcaev3.pdf. Accessed February 10, 2012.
33. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer et al. New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 2000 205 216
34. C.W. Choi, K. Choi, and J.H. Seo et al. Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas Am J Clin Oncol 23 2000 425 428
35. V. Gebbia, F. Giuliani, and E. Maiello et al. Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study J Clin Oncol 19 2001 4089 4091
36. C. Penz, G.V. Kornek, and M. Raderer et al. Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer Ann Oncol 12 2001 183 186
37. M.L. DeOliveira, S.C. Cunningham, and J.L. Cameron et al. Cholangiocarcinoma: thirty-one year experience with 564 patients at a single institution Ann Surg 245 2007 755 762
38. T. Isa, T. Kusano, and H. Shimoji et al. Predictive factors for long-term survival in patients with intrahepatic cholangiocarinoma Am J Surg 181 2001 507 511
39. NCCN Practice Guidelines in Oncology. Hepatobiliary Cancers, v.1.2013. Available at: http://www.nccn.org/professionals/physician-gls/f-guidelines.asp. Accessed: January 14, 2014.
40. J. Valle, H. Wasan, and D.H. Palmer et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer N Engl J Med 362 2010 1273 1281
41. F. Eckel, and R.M. Schmid Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials Br J Cancer 96 2007 896 902
42. S.M. Russo, J.E. Tepper, and A.S. Baldwin Jr. et al. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-κB Int J Radiat Oncol Biol Phys 50 2001 183 193
43. R.J. Bold, S. Virudachalam, and D.J. McConkey Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome J Surg Res 100 2001 11 17
44. J.C. Cusack, R. Liu, and M. Houston et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341 Cancer Res 61 2001 3535 3540
45. P.M. Voorhees, E.C. Dees, and B. O'Neil et al. The proteasome as a target for cancer therapy Clin Cancer Res 9 2003 6316 6325
46. J.-L. Harousseau, M. Attal, and H. Avet-Loiseau et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial J Clin Oncol 28 2010 4621 4629
47. P. Sonneveld, I. Schmidt-Wolf, and B. van der Holt et al. HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, doxorubicin, dexamethasone (PAD) vs VAD followed by high-dose melphalan (HDM) and maintenance with bortezomib or thalidomide in patients with newly diagnosed multiple myeloma (MM) Blood (ASH Annual Meeting Abstracts) 116 2010 40
48. J.F. San Miguel, R. Schlag, and N.K. Khuageva et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma N Engl J Med 359 2008 906 917
49. M. Cavo, P. Tacchetti, and F. Patriarca et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study Lancet 376 2010 2075 2085
50. R.Z. Orlowski, A. Nagler, and P. Sonneveld et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression J Clin Oncol 25 2007 3892 3901